Document Detail

The metabolic syndrome in overweight epileptic patients treated with valproic acid.
MedLine Citation:
PMID:  19682024     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate the presence of metabolic syndrome (MS) in children and adolescents treated with valproate (VPA). METHODS: One hundred fourteen patients (54 male and 60 female) were studied. These patients were followed from the beginning of therapy for at least 24 months; at the end of follow-up, 46 patients (40.4%) had a considerable increase in body weight, whereas the other patients (59.6%) remained with the same weight. The MS was defined as having at least three of the following: abdominal obesity, dyslipidemia, glucose intolerance, and hypertension. RESULTS: Forty-six patients developed obesity; 20 (43.5%) of 46 patients developed MS. Abnormal glucose homeostasis was identified in 45% of patients. High total serum cholesterol concentrations were noted in 10 (50%), high serum triglyceride concentrations in 7 (35%), and low high-density lipoprotein (HDL) in 15 (75%) of the 20 subjects with MS. However, there were no significant differences in the features of MS between boys and girls with MS. CONCLUSIONS: Patients who gain weight during VPA therapy can develop MS with a possible risk of cardiovascular disease.
Alberto Verrotti; Rossella Manco; Sergio Agostinelli; Giangennaro Coppola; Francesco Chiarelli
Related Documents :
16513684 - Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in ...
10458494 - Detection of serum antibody against arrestin from patients with acute disseminated ence...
7362484 - Modified snake venom in amyotrophic lateral sclerosis. lack of clinical effectiveness.
2937754 - Lymphocytoplasmapheresis in multiple sclerosis: one-year results in 6 patients.
20857114 - Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma.
12581684 - Novel management strategy for patients with suspected pulmonary embolism.
Publication Detail:
Type:  Journal Article     Date:  2009-07-20
Journal Detail:
Title:  Epilepsia     Volume:  51     ISSN:  1528-1167     ISO Abbreviation:  Epilepsia     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-03-24     Completed Date:  2010-04-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2983306R     Medline TA:  Epilepsia     Country:  United States    
Other Details:
Languages:  eng     Pagination:  268-73     Citation Subset:  IM    
Department of Pediatrics, University of Chieti, Chieti, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticonvulsants / adverse effects*,  therapeutic use
Body Mass Index
Cardiovascular Diseases / etiology
Dyslipidemias / chemically induced,  epidemiology
Epilepsy / drug therapy*,  epidemiology
Glucose Intolerance / chemically induced,  epidemiology
Hypertension / chemically induced,  epidemiology
Metabolic Syndrome X / chemically induced*,  epidemiology
Obesity / chemically induced,  epidemiology
Overweight / chemically induced*
Risk Factors
Valproic Acid / adverse effects*,  therapeutic use
Reg. No./Substance:
0/Anticonvulsants; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Factors influencing rural versus metropolitan work choices for emergency physicians.
Next Document:  Treatment of early and late kainic-acid induced status epilepticus with the noncompetitive AMPA rece...